1. Home
  2. HTFL vs WVE Comparison

HTFL vs WVE Comparison

Compare HTFL & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HTFL

Heartflow Inc.

N/A

Current Price

$27.79

Market Cap

2.4B

Sector

N/A

ML Signal

N/A

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$13.38

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HTFL
WVE
Founded
2007
2012
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.4B
IPO Year
2025
2015

Fundamental Metrics

Financial Performance
Metric
HTFL
WVE
Price
$27.79
$13.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
16
Target Price
$39.20
$30.56
AVG Volume (30 Days)
1.5M
3.8M
Earning Date
03-27-2026
03-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$161,881,000.00
$109,230,000.00
Revenue This Year
$40.42
N/A
Revenue Next Year
$22.73
$16.10
P/E Ratio
N/A
N/A
Revenue Growth
85.70
103.75
52 Week Low
$25.38
$5.28
52 Week High
$41.22
$21.73

Technical Indicators

Market Signals
Indicator
HTFL
WVE
Relative Strength Index (RSI) 30.33 46.02
Support Level $27.45 $12.70
Resistance Level $30.19 $14.56
Average True Range (ATR) 1.98 0.78
MACD -0.84 -0.07
Stochastic Oscillator 1.35 37.06

Price Performance

Historical Comparison
HTFL
WVE

About HTFL Heartflow Inc.

HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: